Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601633 | 0.90 | CNR2 (0.43) | CYP11B1CYP11B2KDM4EATML3MBTL1 | |
| SCHEMBL15248404 | 0.85 | KDM4E (0.45) | CYP11B1CYP11B2KDM4EATML3MBTL1 | |
| SCHEMBL7602366 | 0.84 | NR3C1 (0.41) | CYP11B1CYP11B2KDM4EATML3MBTL1 | |
| SCHEMBL7602374 | 0.83 | L3MBTL1 (0.47) | KDM4EATML3MBTL1 | |
| SCHEMBL24926789 | 0.83 | KDM4E (0.42) | KDM4EATML3MBTL1 | |
| SCHEMBL19755350 | 0.82 | L3MBTL1 (0.40) | CYP11B1CYP11B2KDM4EATML3MBTL1 | |
| SCHEMBL24927460 | 0.81 | KDM4E (0.46) | KDM4EATML3MBTL1 | |
| SCHEMBL24927619 | 0.81 | KDM4E (0.46) | KDM4EATML3MBTL1 | |
| SCHEMBL24927638 | 0.81 | ALDH1A1 (0.43) | KDM4EATML3MBTL1 | |
| SCHEMBL24927287 | 0.81 | KDM4E (0.42) | KDM4EATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183793-B2 | Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183793-B2 | Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110050118-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110050118-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| WO-2008026614-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110050118-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | ALAD, CYP2C9, CYP1A1 | CYP11B1 157/4885CYP11B2 178/4885KDM4E 2175/4885 |
| US-20080107918-A1 | METHOD FOR SYNTHESIZING ANTHRACENE DERIVATIVE AND ANTHRACENE DERIVATIVE, LIGHT EMITTING ELEMENT, LIGHT EMITTING DEVICE, ELECTRONIC DEVICE | ALAD, CYP2C9, CYP1A1 | CYP11B1 157/4885CYP11B2 178/4885KDM4E 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.